A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12)
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma
- Focus Therapeutic Use
- Acronyms ZUMA-12
- Sponsors Kite Pharma
- 06 Nov 2019 Planned End Date changed from 1 Jan 2035 to 1 Feb 2036.
- 06 Nov 2019 Planned primary completion date changed from 1 Aug 2020 to 1 Feb 2021.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.